Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
about
Thalidomide analogues as anticancer drugsRecent clinical studies of the immunomodulatory drug (IMiD) lenalidomideDoxorubicin and dexamethasone followed by thalidomide and dexamethasone is an effective well tolerated initial therapy for multiple myelomaHigh-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.Thalidomide in combination with vincristine, epirubicin and dexamethasone (VED) for previously untreated patients with multiple myeloma.Low-dose thalidomide plus low-dose dexamethasone therapy in patients with refractory multiple myeloma.Pomalidomide is active in the treatment of anemia associated with myelofibrosisA phase-2 trial of low-dose pomalidomide in myelofibrosis.Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III/IV lung cancer.Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations.Adverse effects of thalidomide administration, in patients with myeloma multiplex?Treatment outcome of thalidomide based regimens in newly diagnosed and relapsed/refractory non-transplant multiple myeloma patients: a single center experience from Thailand.IL-6 and MYC collaborate in plasma cell tumor formation in mice.Long-term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the intergroupe francophone du myelome, southwest oncology group, and university of arkansas for medical sciencesArterial and venous thrombosis in monoclonal gammopathy of undetermined significance and multiple myeloma: a population-based studyRisk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.Anti-angiogenesis therapies: their potential in cancer managementResidual serum monoclonal protein predicts progression-free survival in patients with previously untreated multiple myelomaManagement of thalidomide toxicity.PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma.Racial disparities in incidence and outcome in multiple myeloma: a population-based study.Thalidomide dosing in patients with relapsed or refractory multiple myeloma.Thalidomide for erythema nodosum leprosum and other applications.Novel therapeutic approaches for multiple myeloma.Haematopoietic stem cell transplantation as first-line treatment in myeloma: a global perspective of current concepts and future possibilitiesThalidomide and its derivatives: new promise for multiple myeloma.A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.Bone-Specific Alkaline Phosphatase Levels among Patients with Multiple Myeloma Receiving Various Therapy Options.Stem cell transplantation for multiple myeloma.Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myelomaThalidomide for the treatment of multiple myeloma.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaNonmyeloablative unrelated donor hematopoietic cell transplantation to treat patients with poor-risk, relapsed, or refractory multiple myeloma.Evolving treatment strategies for myeloma.Induction therapy and stem cell mobilization in patients with newly diagnosed multiple myeloma.Management of thrombosis in cancer: primary prevention and secondary prophylaxis.Thalidomide and immunomodulatory drugs in the treatment of cancer.Thalidomide: present and future in multiple myeloma.
P2860
Q24670383-9230BB42-5795-43CC-B3D5-C6EABE7E07B5Q28192646-8314B750-0799-4958-92B9-CE7665D9E00EQ28194391-C1AD985E-0B49-4876-AFDF-C99E1BEC4531Q31032765-9471310D-41F5-4DE4-B600-30B512BF3A71Q33151135-2AA89273-82D3-4155-A2B7-F7B3DB7BA46FQ33364235-CABDD9C7-300A-47C6-9DA0-43BD43A37F88Q33376008-4B001CEE-B1E7-4595-874E-BBC3C9440A9DQ33385644-C3A7D6A1-AA98-45FD-93B8-207E46AF84A7Q33392689-57B59D18-A9DF-45B3-B281-B1055A10915BQ33399333-E921DE07-F6DC-4BEF-9AF0-04EABAC4FB8CQ33632270-3C8EDAB2-3DC7-4938-A90C-BEC06103F39CQ33669639-7D2E2807-AE8C-4195-9836-38C9CE188538Q33687489-D45652D6-46D5-454D-97E2-777F30992469Q33706389-72058810-62EB-45C0-810A-E7BFDEEEF8F3Q33710994-F29D281A-0734-4844-81B4-433A07533F46Q33931754-625E74A9-767F-4268-B2A2-6FF238AFCBE3Q33942495-FBAE6ED6-840E-4BBD-AAAE-03CF76EC6617Q33956056-5768C556-86DE-472F-B3C3-FA204F5ED973Q34001363-FC85FF9F-D711-4D4E-BA42-820FF1823B22Q34343991-C11C2304-A8EE-4E29-ABDF-832FC14AD98FQ34426066-1314660B-6E58-48C6-BE8A-ED71F47FDD9AQ34541680-F79ABBDA-7128-477B-BAEC-E4FDD54756E5Q35092960-511EB1EF-AFFD-40F8-AD59-169A9F65EEFBQ35101473-CBD5F30E-404F-435A-B3D3-D8801BA94BE0Q35170935-BAC4D9DD-2940-4166-B9C6-53B29CDA3166Q35569350-15884801-354E-4AB8-9143-E4A9A211F67AQ35569462-AF2D5B66-AC88-41C1-A9A4-A2235D871A1CQ35597057-C4490ECF-046C-4184-95B5-CB2CEBB152A2Q35678932-CF8D8331-8D6A-4114-8AED-338B352774A8Q35692626-9BECE106-7149-425A-A7F6-5E4E83D7A474Q35848146-28EC5D46-0CAE-49A3-983A-51B44064FB44Q35848744-52F508F4-21A3-4362-BF14-659806FF37C8Q35870500-E2964523-74C2-483B-B25D-7A1861758354Q35907767-40001892-AF10-4773-915F-03B52D7757A2Q35946619-140914CB-51C8-48BC-833A-BD16F8FBB94DQ36012354-6F04D4FB-C434-4BB0-BF52-859D969B3339Q36014687-702F2FC5-901E-465D-8F01-F46D0CF3736BQ36018537-149F82F1-FF73-4451-967A-85B57733928AQ36040871-FE585CF7-9BE5-4DE1-8798-52652AF4FA43Q36066131-AB1891F8-49E2-4A1A-B9DB-8E65A31DD878
P2860
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
@en
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
@nl
type
label
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
@en
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
@nl
prefLabel
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
@en
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
@nl
P2093
P50
P356
P1476
Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.
@en
P2093
John A Lust
Nancy Iturria
Philip R Greipp
Susan Geyer
Thomas E Witzig
P304
P356
10.1200/JCO.2002.02.116
P407
P50
P577
2002-11-01T00:00:00Z